ArticleCureus2025
Observed Reduction in Urinary Toxin Excretion With Extracorporeal Blood Oxygenation and Ozonation (EBOO) Treatment in an 88-Year-Old With Chronic Anemia: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal blood oxygenation and ozonation (EBOO) is a hemodialysis-adjacent ex vivo filtration system. We present a case of an 88-year-old female with chronic iron-deficiency anemia with high urinary levels of mycotoxins, heavy metals, and other environmental toxins. She underwent two distinct series of three sequential EBOO treatments, with interval monitoring of her urinary toxin/creatinine ratios (µg/g) at baseline, after completion of EBOO series I, and after completion of EBOO series II. The average decline from baseline to completion of EBOO series II was 64.8% for the mycotoxins, 25.7% for the heavy metals, and 55.1% for the environmental toxins. Though there was no control for ongoing exposure, all of her toxin levels ultimately decreased except nickel. Her hemoglobin levels remained largely unchanged over the course of treatment. Thus, EBOO should be considered a potential therapy in patients with environmental toxicities that may be contributing to chronic conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.